- Advertisement -
In their race to own the weight-loss market, pharmaceutical companies are innovating at breakneck speed.
The inception of so-called GLP-1 drugs — a shorthand for glucagon-like peptide-1 agonists — which can help users rapidly lose up to 20 percent of their total weight has created a veritable arms race amongst the world’s leading drug makers. All want to create the most effective and widely-adopted iteration. While Novo Nordisk’s Ozempic may be the best-known, competitors like Eli…
